未找到相关数据
Potential remains for PPAR-targeted drugs
被引：34
作者：
Jones, Dan
机构：
关键词：
D O I：
10.1038/nrd3271
中图分类号：
Q81 [生物工程学（生物技术）];
Q93 [微生物学];
学科分类号：
071005 ;
0836 ;
090102 ;
100705 ;
摘要：
The controversy over the diabetes drug rosiglitazone (Avandia; GlaxoSmithKline), a peroxisome proliferator-activated receptor-γ agonist, has undermined confidence in developing drugs that target this family of nuclear receptors, but some companies still see promise in the field.
引用
收藏
页码：668 / 669
页数：2
相关论文